Longeveron (LGVN) Cash & Current Investments (2021 - 2026)
Longeveron's (LGVN) quarterly Cash & Current Investments came in at $15.8 million in Q1 2026, up 9.99% year-on-year from $14.3 million in Q1 2025, and up 238.08% quarter-over-quarter from $4.7 million in Q4 2025.
Longeveron (LGVN) Cash & Current Investments (2021 - 2026) Analysis & Trends
Longeveron's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 9.99% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 9.99% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, down 75.76% from the prior year.
- Cash & Current Investments grew to $15.8 million in Q1 2026 per LGVN's latest filing, from $4.7 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $22.8 million in Q3 2024 and bottomed at $2.3 million in Q1 2024.
- The 5-year median for Cash & Current Investments is $9.8 million (2025), against an average of $10.8 million.
- Biggest YoY gain for Cash & Current Investments was 525.36% in 2025; the steepest drop was 75.76% in 2025.
- Year by year, Cash & Current Investments stood at $19.7 million in 2022, then plunged by 72.73% to $5.4 million in 2023, then soared by 258.74% to $19.2 million in 2024, then tumbled by 75.76% to $4.7 million in 2025, then soared by 238.08% to $15.8 million in 2026.
- Per Business Quant, the three latest LGVN Cash & Current Investments figures stand at $15.8 million (Q1 2026), $4.7 million (Q4 2025), and $9.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 | 15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.76 Mn |
| Dec 31, 2025 | 4.66 Mn |
| Sep 30, 2025 | 9.24 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Mar 31, 2025 | 14.33 Mn |
| Dec 31, 2024 | 19.23 Mn |
| Sep 30, 2024 | 22.78 Mn |
| Jun 30, 2024 | 12.40 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Dec 31, 2023 | 5.36 Mn |
| Sep 30, 2023 | 3.93 Mn |
| Jun 30, 2023 | 8.66 Mn |
| Mar 31, 2023 | 2.30 Mn |
| Dec 31, 2022 | 19.66 Mn |
| Dec 31, 2021 | 35.04 Mn |